ANS' Newest Lead, Lamitrode Tripole 8, Allows Precision in Pain Treatment
2004年11月23日 - 12:34AM
PRニュース・ワイアー (英語)
ANS' Newest Lead, Lamitrode Tripole 8, Allows Precision in Pain
Treatment Unique Design Provides Greater Accuracy and Control to
Enhance the Performance of ANS Spinal Cord Stimulators PLANO,
Texas, Nov. 22 /PRNewswire-FirstCall/ -- Advanced Neuromodulation
Systems, Inc. (NASDAQ:ANSI) (ANS) today introduced the Lamitrode(R)
Tripole 8 lead, a significant addition to its growing family of
leads. The first of its kind on the market, this innovative
surgical lead features a three-column electrode array, which allows
clinicians to direct the stimulation current more precisely to
nerve structures deep in the spinal cord. "We designed the Tripole
8 to facilitate precise delivery of stimulation to the low back
area," said Claudio A. Feler, M.D. and designer of the new lead.
"The resulting improved coverage is intended to help physicians
enhance therapy for their patients." The six independently
controlled midline contacts and optional anodal guards (lateral
contacts used as a single anode) give the Tripole 8 lead a
tremendous amount of programming flexibility. The tripolar
configuration is designed to allow the electrical field to be
steered longitudinally along the lead and laterally across the lead
array when used in conjunction with the ANS propriety MultiStim(R)
technology. This "steerability" helps to confine the stimulation
field between electrodes, making it possible for clinicians to more
effectively target the back fibers that cause pain and to provide a
broader area of stimulation coverage. "The Lamitrode(R) Tripole 8
lead is another example of our cooperative efforts with renowned
physicians to develop cutting-edge neurostimulation technology -- a
top priority for ANS, as we strive to create superior products that
address significant clinical needs," said ANS President and CEO
Chris Chavez. About chronic pain Chronic pain affects an estimated
50 million Americans, of whom more than half are partially or
totally disabled. At present, approximately $100 billion are spent
in the U.S. on the diagnosis and treatment of chronic pain, which
represents the most common indication for spinal cord stimulation
therapy. The 106th U.S. Congress has declared this the "Decade of
Pain Control and Research," helping to bring spinal cord
stimulation to the forefront as a viable and effective option in
the treatment of chronic pain. About Advanced Neuromodulation
Systems (ANS) Advanced Neuromodulation Systems, Inc. designs,
develops, manufactures and markets implantable systems used to
manage chronic intractable pain and other disorders of the central
nervous system. A technology leader in the neuromodulation
industry, ANS offers a family of proprietary neurostimulation
devices and implantable drug pumps for an expanding range of
therapeutic applications. ANS was recently named among FORTUNE's
100 Fastest Growing Companies and has been recognized among Forbes'
200 Best Small Companies for two consecutive years. Frost &
Sullivan also recently honored the company with its Product
Innovation Award. Additional information is available at
http://www.ans-medical.com/ . DATASOURCE: Advanced Neuromodulation
Systems, Inc. CONTACT: Stephanie Coggin, +1-972-716-0500 x 17, or ,
for Advanced Neuromodulation Systems, Inc. Web site:
http://www.ans-medical.com/
Copyright
Advanced Neuromodulation (NASDAQ:ANSI)
過去 株価チャート
から 5 2024 まで 6 2024
Advanced Neuromodulation (NASDAQ:ANSI)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Advanced Neuromodulation Systems (MM) (ナスダック市場): 0 recent articles
その他のAdvanced Neuromodulation Systems (MM)ニュース記事